Global Cell Penetrating Peptide Market Report 2024

The cell penetration peptide market size has grown rapidly in recent years. It will grow from $1.63 billion in 2023 to $1.87 billion in 2024 at a compound annual growth rate (CAGR) of 14.9%. The increase during the historic period can be attributed to factors such as an enhanced understanding of cellular uptake mechanisms, a growing demand for targeted drug delivery systems, an increase in the prevalence of chronic diseases, the emergence of personalized medicine approaches, and the expansion of research and development activities in the pharmaceutical sector.

The cell penetration peptide market size is expected to see rapid growth in the next few years. It will grow to $3.31 billion in 2028 at a compound annual growth rate (CAGR) of 15.3%. The rise in the forecast period can be attributed to several factors, including the development of novel peptide-based therapeutics for rare diseases, increased investment in healthcare infrastructure in emerging markets, a growing demand for peptide-based vaccines and immunotherapies, regulatory initiatives aimed at streamlining approval processes for peptide drugs, and a shift towards sustainable and biodegradable peptide delivery systems. Major trends expected in this period include the customization of cell-penetrating peptides for specific therapeutic applications, the exploration of cell-penetrating peptides as tools for intracellular delivery, the integration of artificial intelligence and machine learning in peptide design, the integration of cell-penetrating peptides into therapeutic strategies, and the adoption of novel delivery routes for peptides.

The growth of the cell penetration peptide market is expected to be driven by increasing investment in health research and development (R&D). Health R&D involves systematic exploration and experimentation to advance scientific understanding and develop innovative solutions for better healthcare outcomes. This increase in R&D investment is fueled by healthcare needs, technological advancements, global health priorities, investment incentives, and economic opportunities. Cell penetration peptides play a crucial role in advancing health R&D, particularly in drug delivery, gene therapy, vaccine development, molecular imaging, and cellular research. For example, in December 2023, state government agencies in the US allocated $1.1 billion towards health R&D in fiscal year 2022, marking a 2.2% increase from fiscal year 2021's $1.07 billion expenditure. Hence, the rise in R&D activities is propelling the growth of the cell penetration peptide market.

Key players in the cell penetration peptide market are focusing on innovative platforms such as peptide drug discovery platforms to gain a competitive advantage. These platforms streamline the identification, design, optimization, and evaluation of CPP-based therapeutics. For instance, in May 2023, Fujitsu Limited introduced the Biodrug Design Accelerator, a platform aiding peptide drug discovery scientists in pharmaceutical firms by expediting and enhancing the efficiency of peptide drug development, particularly through the 'design, make, test, analyze' (DMTA) cycles. It facilitates communication among scientists regarding synthesis and testing, compatible with HELM, a method for describing complex biomolecules.

In December 2023, Invaio Sciences, a US company specializing in human health and digital innovation solutions, acquired Peptyde Bio for an undisclosed sum. This acquisition equips Invaio with a strong platform and intellectual property portfolio, enabling the company to expedite the development and discovery of biologically active peptides. Peptyde Bio, also based in the US, focuses on discovering, designing, and characterizing novel cell-penetrating peptides.

Major companies operating in the cell penetrating peptide market are Thermo Fisher Scientific Inc., Novo Nordisk A/S, Merck KGaA, Corden Pharma GmbH, Sarepta Therapeutics Inc., GenScript Biotech Corporation, Bachem Holding AG, R&D Systems Inc., PolyPeptide Laboratories AB, PeptiDream Inc., Revance Therapeutics Inc., CPC Scientific Inc., Tocris Bioscience, Bio-Synthesis Inc., AnaSpec Inc., Avidity Biosciences Inc., Iris Biotech GmbH, PEPperPRINT GmbH, Chemos GmbH & Co. KG, Creative Peptides GmbH, ProImmune Ltd., Pepscan Inc., The Cupid Peptide Company, AltaBioscience Ltd., Peptomyc.

North America was the largest region in the cell penetrating peptide market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell penetrating peptide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell penetrating peptide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cell-penetrating peptides (CPPs), also referred to as protein transduction domains (PTDs) or membrane translocation peptides, are short peptides typically comprising 5 to 30 amino acids. They possess the capability to traverse cell membranes and facilitate the intracellular delivery of diverse cargo molecules, including proteins, nucleic acids, and small molecules. These peptides enable the transport of various cargoes across biological barriers such as the plasma membrane, endosomal membranes, and nuclear envelope, without causing significant cellular damage.

The primary types of cell-penetrating peptides include synthetic cell-penetrating peptides, protein-derived cell-penetrating peptides, and chimeric cell-penetrating peptides. Synthetic cell-penetrating peptides are artificially created in laboratory settings, often through chemical synthesis methods. These peptides find applications in drug delivery, gene delivery, diagnostics, molecular imaging, and other pharmaceutical and biotechnology-related applications, catering to entities such as pharmaceutical and biotechnology companies, contract research organizations (CROs), hospitals and clinics, among others.

The cell-penetrating peptide market research report is one of a series of new reports that provides cell-penetrating peptide market statistics, including cell-penetrating peptide industry global market size, regional shares, competitors with cell-penetrating peptide market share, detailed cell-penetrating peptide market segments, market trends, and opportunities, and any further data you may need to thrive in the cell-penetrating peptide industry. This cell-penetrating peptide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell-penetrating peptide market consists of revenues earned by entities by providing services such as custom synthesis services, peptide conjugation services, preclinical and clinical testing services, and delivery system development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell penetrating peptide market also includes sales of automated peptide synthesizers, mass spectrometers, fluorescence microscopes, and flow cytometers which are used in providing cell penetrating peptide services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.